TherapeuticsMD Inc Asset Resilience Ratio
TherapeuticsMD Inc asset resilience ratio. TherapeuticsMD Inc (TXMD) has an Asset Resilience Ratio of 0.13% as of June 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See TherapeuticsMD Inc (TXMD) defensive interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of TherapeuticsMD Inc (2011–2017)
Asset resilience ratio of TherapeuticsMD Inc from 2011 to 2017. This chart shows how TherapeuticsMD Inc's Asset Resilience Ratio has changed over time. Read TherapeuticsMD Inc (TXMD) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down TherapeuticsMD Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see TherapeuticsMD Inc (TXMD) total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $68.41K | 0.13% |
| Total Liquid Assets | $68.41K | 0.13% |
Asset Resilience Insights
- Limited Liquidity: TherapeuticsMD Inc maintains only 0.13% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
TherapeuticsMD Inc Industry Peers by Asset Resilience Ratio
Compare TherapeuticsMD Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211 |
Drug Manufacturers - Specialty & Generic | 11.84% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Bide Pharmatech Co. Ltd. A
SHG:688073 |
Drug Manufacturers - Specialty & Generic | 9.46% |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976 |
Drug Manufacturers - Specialty & Generic | 20.61% |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365 |
Drug Manufacturers - Specialty & Generic | 30.38% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.42% |
TherapeuticsMD Inc Asset Resilience Ratio by Year (2011–2017)
TherapeuticsMD Inc asset resilience ratio by year from 2011 to 2017. The table below shows the annual Asset Resilience Ratio data for TherapeuticsMD Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2017-12-31 | 0.00% | $0.00 | $143.23 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $142.47 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $73.73 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $59.08 Million | -- |
| 2013-12-31 | 0.00% | $0.00 | $62.02 Million | -- |
| 2012-12-31 | 0.00% | $0.00 | $5.82 Million | -- |
| 2011-12-31 | 0.00% | $0.00 | $1.44 Million | -- |
About TherapeuticsMD Inc
TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States and internationally. Its products portfolio includes IMVEXXY for the treatment of moderate-to-severe dyspareunia, a symptom of vulvar and vaginal atrophy due to menopause; BIJUVA to treat moderate-to-severe vasomotor symptoms due to menopause in women with a uterus; and ANNOVERA, a ring-shaped contraceptive vag… Read more